Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.
about
The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemiaComplement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement.Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cFrontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomes.First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab.The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.The spectrum of use of rituximab in chronic lymphocytic leukemiaRole of rituximab in first-line treatment of chronic lymphocytic leukemia.Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies?Choosing first-line therapy for chronic lymphocytic leukemia.Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.Prophylaxis and Treatment of Pneumocystis jiroveci Pneumonia in Lymphoma Patients Subjected to Rituximab-Contained Therapy: A Systemic Review and Meta-Analysis.Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL).Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence.Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates.Imprime PGG-Mediated Anti-Cancer Immune Activation Requires Immune Complex FormationRole of CD20 monoclonal antibodies in previously untreated chronic lymphocytic leukemia.Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach.Quantification of expression of antigens targeted by antibody-based therapy in chronic lymphocytic leukemia.A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908).A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention.Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia.Understanding and circumventing resistance to anticancer monoclonal antibodies.New angles of attack in the fight against chronic lymphocytic leukemia: the advent of novel non-chemotherapeutic agents.What is the best frontline therapy for patients with CLL and 17p deletion?Biologic agent activity in chronic lymphocytic leukemia: a framework for future therapies.Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia?Rituximab: current status as therapy for malignant and benign hematologic disorders.What do we do with chronic lymphocytic leukemia with 17p deletion?B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities.An update on current and prospective immunotherapies for chronic lymphocytic leukemia.Cholorambucil versus Cholorambucil Plus Prednisolone as First-Line Therapy of Chronic Lymphocytic Leukemia in West of Iran.Rituximab for the treatment of patients with chronic lymphocytic leukemiaThe emerging therapeutic role of antibody mixtures.Applications of monoclonal antibodies for the treatment of hematological malignancies
P2860
Q24617708-989BEB33-D188-44BC-B870-D570016CFDE0Q30356145-F259B52A-3438-4726-B29F-1895E6EFE769Q30408922-5927A04B-2FE5-4516-B5C4-A7FDAC6056A6Q33396222-8139C1F0-7091-4BAD-8112-BA57BBE93FAEQ33414468-94E77D7F-6D7A-4E35-BCCF-8528E5C45CD7Q33956034-52E21376-54D7-41F6-9EB8-7040B5EA00F4Q34310845-17CCE3A1-36EC-4F07-8A1F-FB090CE63193Q34510030-441A3595-A957-4CB6-B070-DCC5ECB6466DQ34574147-9D1639B9-9C11-4EC7-83EA-3946DB4EA3FDQ34625543-BC9CF283-D5A9-4BD6-9AC0-EA342C7B33E8Q35124844-8CB563AF-466F-40E1-8C32-3491A77B39DDQ35569491-9E7BA745-D943-47A6-A17C-FF4131D9C528Q35613669-00B6AF4B-781D-400A-A0EE-D548233FB820Q35683808-BEBAA715-47AB-4A8D-9BC6-E407AA1CD734Q35766117-A488A6E4-A86C-4655-A127-64BD8D12859AQ36070219-6DB932E6-F91D-4C1D-B275-8685A1AD3F77Q36182299-AAE26B6B-E31D-4915-81F3-E4ACD0842BF7Q36218799-A238FC69-5A54-4413-81CF-947FC21A6428Q36251887-39A35209-E4AF-40E7-8DE8-83D41776001CQ36423833-3DA6BFEC-AF14-4A7D-870D-EF8D75677DB7Q36725445-BB4FA812-AFF8-4AA2-A473-0BAA8B0C273FQ36892621-3E04F91B-AE07-4E18-8BB3-C86BBD7D1491Q37448352-4A7A51BA-012F-45E9-89A1-CC01FD1CA69FQ37559275-01F72896-B5C1-42D1-90A6-63256FBDE906Q37672125-C68F6ED6-8419-4550-BD6B-C4E64AFE0B0BQ37767703-FC380F98-FE7B-442D-B119-488D801CCB6DQ37820433-0615B3A7-77E9-4666-AD46-A88495511005Q37842484-5220E0ED-4B90-4982-8B63-27F683553F37Q37975154-1FBDEC6B-B996-4131-8C68-40E33E646E34Q37984551-CFC02968-59CA-4541-99D6-C5564AB8DB87Q38063170-33987907-901C-41A5-9A7A-044CED804DE6Q38124119-7815C449-B4FB-43C4-8704-C3EBD816ACD7Q38445357-C5378884-02BE-4470-BC15-B2C26F6768E1Q39994604-A8F13100-DDA9-4D3B-817A-385DD6E40DBDQ41241909-A844E626-7F50-43A3-838B-589FECDC6CBFQ46026271-34061FA0-9FFA-497E-98C9-5104A325B7DBQ57904664-B2F40D87-FEE7-4526-B951-ED597C6B68E9
P2860
Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.
@ast
Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.
@en
type
label
Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.
@ast
Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.
@en
prefLabel
Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.
@ast
Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.
@en
P2093
P2860
P356
P1433
P1476
Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.
@en
P2093
Betsy R Laplant
Brian F Kabat
Charla R Secreto
Clive S Zent
Deborah A Bowen
Diane F Jelinek
Neil E Kay
Renee C Tschumper
Tait D Shanafelt
Timothy G Call
P2860
P304
P356
10.1002/CNCR.23824
P407
P577
2008-10-01T00:00:00Z